These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

907 related items for PubMed ID: 26951110

  • 1. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S, Ozturk Sari S, Yegen G, Sormaz IC, Yilmaz I, Poyrazoglu S, Sanlı Y, Giles Senyurek Y, Kapran Y, Mete O.
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [Abstract] [Full Text] [Related]

  • 2. Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.
    Oishi N, Kondo T, Nakazawa T, Mochizuki K, Inoue T, Kasai K, Tahara I, Yabuta T, Hirokawa M, Miyauchi A, Katoh R.
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [Abstract] [Full Text] [Related]

  • 3. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.
    Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, Asahina M, Yamashita A, Tomomasa R, Hayashi T, Arakawa A, Yao T.
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK, Yang JH.
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [Abstract] [Full Text] [Related]

  • 5. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
    Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A.
    Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS, Kim Y, Jeon S, Kim SH, Kim TJ, Lee S, Kim MH, Lim DJ, Lee YS, Jung CK.
    Diagn Pathol; 2016 Feb 09; 11():21. PubMed ID: 26857243
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
    Na HY, Yu HW, Kim W, Moon JH, Ahn CH, Choi SI, Kim YK, Choi JY, Park SY.
    Clin Endocrinol (Oxf); 2022 Jul 09; 97(1):106-115. PubMed ID: 35343605
    [Abstract] [Full Text] [Related]

  • 8. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V.
    Eur J Endocrinol; 2015 Apr 09; 172(4):403-13. PubMed ID: 25583906
    [Abstract] [Full Text] [Related]

  • 9. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O.
    Oncotarget; 2016 Apr 05; 7(14):18346-55. PubMed ID: 26943032
    [Abstract] [Full Text] [Related]

  • 10. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
    Sun J, Zhang J, Lu J, Gao J, Ren X, Teng L, Duan H, Lin Y, Li X, Zhang B, Liang Z.
    PLoS One; 2016 Apr 05; 11(4):e0153319. PubMed ID: 27064992
    [Abstract] [Full Text] [Related]

  • 11. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP.
    Laryngoscope; 2014 Sep 05; 124(9):E389-93. PubMed ID: 24604709
    [Abstract] [Full Text] [Related]

  • 12. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M, Yan C, Xiao J, Wang T, Ling R.
    Diagn Pathol; 2019 Jul 12; 14(1):74. PubMed ID: 31300059
    [Abstract] [Full Text] [Related]

  • 13. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 12; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 14. Gene Expression Profiles of AHNAK2, DCSTAMP, FN1, and TERT Correlate With Mutational Status and Recurrence in Papillary Thyroid Carcinoma.
    Staubitz-Vernazza JI, Müller C, Heymans A, Nedwed AS, Schindeldecker M, Hartmann M, Kloth M, Schad A, Roth W, Musholt TJ, Hartmann N.
    Genes Chromosomes Cancer; 2024 Aug 12; 63(8):e23256. PubMed ID: 39193983
    [Abstract] [Full Text] [Related]

  • 15. [BRAF V600E Mutation and TERT Promoter Mutation in Papillary Thyroid Carcinomas and Their Association with Clinicopathological Characteristics].
    Yang T, Chen C, Pan NF, Sun LY, Jiang XL, Li JN, Tang Y, Jiang Y.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec 12; 50(6):919-924. PubMed ID: 31880125
    [Abstract] [Full Text] [Related]

  • 16. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
    Odate T, Oishi N, Kawai M, Tahara I, Mochizuki K, Akaishi J, Ito K, Katoh R, Kondo T.
    Endocr Pathol; 2021 Sep 12; 32(3):347-356. PubMed ID: 33761111
    [Abstract] [Full Text] [Related]

  • 17. Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.
    Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, Hahn S, Park DJ, Park YJ.
    Thyroid; 2017 May 12; 27(5):651-660. PubMed ID: 28181854
    [Abstract] [Full Text] [Related]

  • 18. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A, Ramshankar V, Murherkar K, Vidyarani S, Raghunandhan GC, Das A, Desai PB, Albert K.
    Indian J Cancer; 2017 May 12; 54(1):372-378. PubMed ID: 29199726
    [Abstract] [Full Text] [Related]

  • 19. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY, Sarabia SF, Sayeed H, Patel N, Baalwa J, Athanassaki I, Hernandez JA, Fang E, Quintanilla NM, Roy A, López-Terrada DH.
    Pediatr Dev Pathol; 2016 May 12; 19(2):94-100. PubMed ID: 26366474
    [Abstract] [Full Text] [Related]

  • 20. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
    Melo M, Gaspar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carrilho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P.
    J Clin Endocrinol Metab; 2017 Jun 01; 102(6):1898-1907. PubMed ID: 28323937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.